# Maze Therapeutics, Inc. (MAZE): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Maze Therapeutics, Inc. (MAZE) is 13/100, ranked against 24,000+ stocks in 35 markets (Quality 27, Value 25, Momentum 37, each scored against its sector).

- StockRank: 13/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 27, Value 25, Momentum 37: each a 0-100 percentile within Healthcare.
- Position: #22,945 overall, #2,154 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 31.07 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 10.5M.

Source: https://moatmap.ai/stock/MAZE
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker